Items Tagged ‘lenalidomide’

November 29th, 2016

Darzalex® Approved for Additional Indications in Multiple Myeloma

By

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA indication also requires that daratumumab be used in combination with lenalidomide and dexamethasone, or in combination with bortezomib and dexamethasone. Daratumumab is already approved […]

View full entry

Tags: blood cancer, bortezomib, CASTOR, CD38, Darzalex, dexamethasone, fda, lenalidomide, Multiple Myeloma, News, POLLUX, Recurrent Multiple Myeloma


August 31st, 2016

Revlimid® Reduces Need for Blood Transfusions in Some Myelodysplastic Syndromes

By

The agent Revlimid (lenalidomide) reduces the need for blood transfusions among patients with lower-risk, non-del (5q) myelodysplastic syndromes who are dependent upon red blood cell transfusions, but are not eligible for erythropoiesis-stimulating agents. These results were recently published in the Journal of Clinical Oncology. Myelodysplastic syndromes (MDS) refer to a group of diseases in which […]

View full entry

Tags: clinical trial, General Myelodysplastic Syndrome, lenalidomide, MDS, Myelodysplastic Syndrome, News, RBC, revlimid


December 7th, 2015

FDA Approves Empliciti for Multiple Myeloma

By

The United States Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for the treatment of patients with multiple myeloma who have received prior therapies. The indication specifies that Empliciti is to be used in combination with lenalidomide and dexamethasone for the treatment of patients who have received one to three prior therapies for multiple […]

View full entry

Tags: dexamethasone, elotuzumab, Empliciti, fda, lenalidomide, Multiple Myeloma, News, Recurrent Multiple Myeloma, SLAMF7